Clinical bottom line
Intravenous fosphenytoin is a putative adjunct for acute neuropathic pain management in the emergency department (ED), particularly when conventional analgesics are insufficient or contraindicated. While fosphenytoin’s established role in seizure control is well known, emerging evidence suggests its sodium channel–blocking properties may confer analgesic benefits in neuropathic pain states. However, current data remain limited and largely extrapolated from chronic pain and seizure literature, warranting cautious interpretation. Emergency clinicians should consider fosphenytoin as a potential option in refractory acute neuropathic pain, recognizing that robust, ED-specific trials are lacking and that its use should be individualized with close monitoring.
What the evidence shows
Neuropathic pain in the ED is a challenging clinical entity, often inadequately addressed by standard opioid or non-opioid analgesics (AKTAŞ et al., 2026). Fosphenytoin, a prodrug of phenytoin, acts by stabilizing neuronal membranes through sodium channel blockade, a mechanism shared with other agents used in neuropathic pain such as lidocaine and ketamine (Shanthanna et al., 2012). Although fosphenytoin is primarily indicated for seizure management, its intravenous formulation offers rapid onset and favorable pharmacokinetics, making it a candidate for acute pain scenarios.
Evidence supporting intravenous fosphenytoin for neuropathic pain in the ED is sparse but suggestive. Reviews on intravenous therapies for neuropathic pain highlight the analgesic potential of sodium channel blockers, including fosphenytoin, based on mechanistic rationale and limited clinical reports (Shanthanna et al., 2012). AKTAŞ et al. (2026) emphasize the need for early intervention in neuropathic pain to prevent central sensitization and chronicity, proposing intravenous agents like fosphenytoin as part of multimodal strategies in emergency settings.
Comparatively, other intravenous agents such as ketamine and lidocaine have more established evidence bases for neuropathic pain relief in acute and chronic contexts (Shanthanna et al., 2012; Kelly et al., 2008). However, fosphenytoin’s safety profile, especially its cardiovascular and neurological monitoring requirements, may be more favorable than ketamine in certain populations. Despite these theoretical advantages, no large-scale randomized controlled trials have yet evaluated intravenous fosphenytoin specifically for acute neuropathic pain in the ED.
Caveats and uncertainty
The principal limitation is the paucity of direct clinical evidence assessing intravenous fosphenytoin for acute neuropathic pain in emergency settings. Most data derive from chronic pain management or seizure literature, which may not fully translate to acute ED presentations. The optimal dosing, timing, and patient selection criteria remain undefined.
Safety concerns include potential cardiac arrhythmias, hypotension, and central nervous system side effects, necessitating cardiac monitoring during administration (AKTAŞ et al., 2026). Furthermore, fosphenytoin’s interaction profile and contraindications must be carefully considered. The lack of standardized protocols and clinical guidelines for this indication contributes to variability in practice and uncertainty regarding efficacy.
Additionally, neuropathic pain diagnosis in the ED can be challenging, with overlap between nociceptive and neuropathic mechanisms complicating treatment decisions (Samcam et al., 2016). This diagnostic ambiguity may affect the appropriateness and outcomes of fosphenytoin use.
How this may change practice
If further validated, intravenous fosphenytoin could become a valuable tool for emergency clinicians managing refractory acute neuropathic pain, particularly when first-line analgesics fail or are contraindicated. Its rapid onset and intravenous route suit the ED environment, potentially improving patient comfort and reducing opioid reliance.
Emergency departments might integrate fosphenytoin into multimodal analgesic protocols, emphasizing early recognition of neuropathic pain features and tailored pharmacotherapy. However, implementation should be cautious and accompanied by staff education on monitoring requirements and adverse effect management.
Future research should focus on randomized controlled trials comparing intravenous fosphenytoin with established neuropathic pain treatments in the ED, elucidating optimal dosing regimens and safety profiles. Until then, fosphenytoin use for acute neuropathic pain remains an off-label, hypothesis-generating approach warranting close clinical judgment.